Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. (Q38644587)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

H E Lebovitz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

8 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

333-347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic strategies based on glucagon-like peptide 1.

1 March 2020

cites work

1 reference

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary

21 January 2018

1 reference

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide

21 January 2018

1 reference

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

21 January 2018

1 reference

Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8

21 January 2018

1 reference

Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

21 January 2018

1 reference

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV

21 January 2018

1 reference

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

21 January 2018

1 reference

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

21 January 2018

1 reference

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

21 January 2018

1 reference

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

21 January 2018

1 reference

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

21 January 2018

1 reference

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

Evogliptin: First Global Approval

21 January 2018

1 reference

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.

21 January 2018

1 reference

Trelagliptin: First Global Approval

21 January 2018

1 reference

Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

21 January 2018

1 reference

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

21 January 2018

1 reference

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin

21 January 2018

1 reference

Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

21 January 2018

1 reference

Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver

21 January 2018

1 reference

Standards of medical care in diabetes--2014

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.

21 January 2018

1 reference

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison

21 January 2018

1 reference

Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

21 January 2018

1 reference

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

21 January 2018

1 reference

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

21 January 2018

1 reference

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

21 January 2018

1 reference

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

21 January 2018

1 reference

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

21 January 2018

1 reference

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor

21 January 2018

1 reference

Review. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator.

21 January 2018

1 reference

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

21 January 2018

1 reference

Treating diabetes today: a matter of selectivity of sulphonylureas

21 January 2018

1 reference

Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands

21 January 2018

1 reference

21 January 2018

Oral Antidiabetic Agents

1 reference

Variations in tissue selectivity amongst insulin secretagogues: a systematic review

21 January 2018

1 reference

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis

21 January 2018

1 reference

Emergency hospitalizations for adverse drug events in older Americans

21 January 2018

1 reference

Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England

21 January 2018

1 reference

Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk

21 January 2018

1 reference

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

21 January 2018

1 reference

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.

21 January 2018

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study

21 January 2018

1 reference

Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis

21 January 2018

1 reference

Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study

21 January 2018

1 reference

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease

21 January 2018

1 reference

Impairment of myocardial protection in type 2 diabetic patients

21 January 2018

1 reference

Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury

21 January 2018

1 reference

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

21 January 2018

1 reference

Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study

21 January 2018

1 reference

Mortality risk among sulfonylureas: a systematic review and network meta-analysis

21 January 2018

1 reference

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value

21 January 2018

1 reference

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

21 January 2018

1 reference

Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

21 January 2018

1 reference

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.

21 January 2018

1 reference

Treating diabetes mellitus in older and oldest old patients

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

21 January 2018

1 reference

Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.

21 January 2018

1 reference

Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study.

21 January 2018

1 reference

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.

21 January 2018

1 reference

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.

21 January 2018

1 reference

Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study

21 January 2018

1 reference

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study

21 January 2018

1 reference

Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia

21 January 2018

1 reference

Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans

21 January 2018

1 reference

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

21 January 2018

1 reference

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

21 January 2018

1 reference

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

21 January 2018

1 reference

Heterozygous ABCC8 mutations are a cause of MODY

21 January 2018

1 reference

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12610

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26597596%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference